Key points

GLP-1 drugs show potential to treat substance use disorders.

These effects appear to be mediated at least in part through the modulation of reward pathways in the CNS.

Early results show reductions in cravings, substance use, and other related outcomes.

Glucagon-like peptide-1 (GLP-1) is a hormone responsible for most of the insulin release after consuming a meal. Its effects are mediated by activation of GLP-1 receptors (GLP-1Rs) in the central nervous system , which help regulate hunger signals that prompt people to eat when hungry and stop when satisfied (Fig. 1). The introduction of GLP-1 therapeutics has revolutionized the treatment of type 2 diabetes and obesity, with other potential indications under investigation.

One such additional indication is the treatment of

See Full Page